Cargando…

Selective androgen receptor modulators: the future of androgen therapy?

Selective androgen receptor modulators (SARMs) are small molecule drugs that function as either androgen receptor (AR) agonists or antagonists. Variability in AR regulatory proteins in target tissues permits SARMs to selectively elicit anabolic benefits while eschewing the pitfalls of traditional an...

Descripción completa

Detalles Bibliográficos
Autores principales: Christiansen, Andrew R., Lipshultz, Larry I., Hotaling, James M., Pastuszak, Alexander W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108998/
https://www.ncbi.nlm.nih.gov/pubmed/32257854
http://dx.doi.org/10.21037/tau.2019.11.02
_version_ 1783512867068182528
author Christiansen, Andrew R.
Lipshultz, Larry I.
Hotaling, James M.
Pastuszak, Alexander W.
author_facet Christiansen, Andrew R.
Lipshultz, Larry I.
Hotaling, James M.
Pastuszak, Alexander W.
author_sort Christiansen, Andrew R.
collection PubMed
description Selective androgen receptor modulators (SARMs) are small molecule drugs that function as either androgen receptor (AR) agonists or antagonists. Variability in AR regulatory proteins in target tissues permits SARMs to selectively elicit anabolic benefits while eschewing the pitfalls of traditional androgen therapy. SARMs have few side effects and excellent oral and transdermal bioavailability and may, therefore, represent viable alternatives to current androgen therapies. SARMs have been studied as possible therapies for many conditions, including osteoporosis, Alzheimer’s disease, breast cancer, stress urinary incontinence (SUI), prostate cancer (PCa), benign prostatic hyperplasia (BPH), male contraception, hypogonadism, Duchenne muscular dystrophy (DMD), and sarcopenia/muscle wasting/cancer cachexia. While there are no indications for SARMs currently approved by the Food and Drug Administration (FDA), many potential applications are still being explored, and results are promising. In this review, we examine the literature assessing the use of SARMS for a number of indications.
format Online
Article
Text
id pubmed-7108998
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-71089982020-04-01 Selective androgen receptor modulators: the future of androgen therapy? Christiansen, Andrew R. Lipshultz, Larry I. Hotaling, James M. Pastuszak, Alexander W. Transl Androl Urol Review Article Selective androgen receptor modulators (SARMs) are small molecule drugs that function as either androgen receptor (AR) agonists or antagonists. Variability in AR regulatory proteins in target tissues permits SARMs to selectively elicit anabolic benefits while eschewing the pitfalls of traditional androgen therapy. SARMs have few side effects and excellent oral and transdermal bioavailability and may, therefore, represent viable alternatives to current androgen therapies. SARMs have been studied as possible therapies for many conditions, including osteoporosis, Alzheimer’s disease, breast cancer, stress urinary incontinence (SUI), prostate cancer (PCa), benign prostatic hyperplasia (BPH), male contraception, hypogonadism, Duchenne muscular dystrophy (DMD), and sarcopenia/muscle wasting/cancer cachexia. While there are no indications for SARMs currently approved by the Food and Drug Administration (FDA), many potential applications are still being explored, and results are promising. In this review, we examine the literature assessing the use of SARMS for a number of indications. AME Publishing Company 2020-03 /pmc/articles/PMC7108998/ /pubmed/32257854 http://dx.doi.org/10.21037/tau.2019.11.02 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Christiansen, Andrew R.
Lipshultz, Larry I.
Hotaling, James M.
Pastuszak, Alexander W.
Selective androgen receptor modulators: the future of androgen therapy?
title Selective androgen receptor modulators: the future of androgen therapy?
title_full Selective androgen receptor modulators: the future of androgen therapy?
title_fullStr Selective androgen receptor modulators: the future of androgen therapy?
title_full_unstemmed Selective androgen receptor modulators: the future of androgen therapy?
title_short Selective androgen receptor modulators: the future of androgen therapy?
title_sort selective androgen receptor modulators: the future of androgen therapy?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108998/
https://www.ncbi.nlm.nih.gov/pubmed/32257854
http://dx.doi.org/10.21037/tau.2019.11.02
work_keys_str_mv AT christiansenandrewr selectiveandrogenreceptormodulatorsthefutureofandrogentherapy
AT lipshultzlarryi selectiveandrogenreceptormodulatorsthefutureofandrogentherapy
AT hotalingjamesm selectiveandrogenreceptormodulatorsthefutureofandrogentherapy
AT pastuszakalexanderw selectiveandrogenreceptormodulatorsthefutureofandrogentherapy